Eikon Therapeutics, Inc. Common Stock (EIKN) vs Prothena Corporation plc (PRTA)

A side-by-side comparison of Eikon Therapeutics, Inc. Common Stock and Prothena Corporation plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Eikon Therapeutics, Inc. Common Stock logo
EIKN
Eikon Therapeutics, Inc. Common Stock
$407M
$7.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Prothena Corporation plc logo
PRTA
Prothena Corporation plc
$420M
$8.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — EIKN vs PRTA

growth of $100 · dividends reinvested · last 1y
EIKN -49.7% (-49.7%/yr)PRTA -7.2% (-7.2%/yr)PRTA compounded faster over this window
6080100120Start $100$50$93
EIKN PRTA

EIKN vs PRTA: by the numbers

  • •PRTA is the larger company ($420M vs $407M market cap).
  • •Both run net losses; EIKN's is the smaller (0.00% vs -80.67% net margin).

Metrics side by side

Valuation

MetricEIKNPRTA
Forward P/EN/A72.91
P/S ratioN/A7.70
P/B ratio0.871.46

Profitability

MetricEIKNPRTA
Gross margin0.00%61.77%
Operating margin0.00%-1905.82%
Net margin0.00%-80.67%
ROE-69.06%-15.33%
ROIC-46.16%-21.36%

Growth (annualized)

MetricEIKNPRTA
Revenue CAGR (5Y)N/A62.57%
Total return CAGR (5Y)N/A-35.08%

Go deeper

Full EIKN analysisFull PRTA analysisInteractive comparison tool

Dig into the metrics

Eikon Therapeutics, Inc. Common Stock ROEProthena ROEEikon Therapeutics, Inc. Common Stock operating marginProthena operating marginEikon Therapeutics, Inc. Common Stock revenue growthProthena revenue growthEikon Therapeutics, Inc. Common Stock free cash flowProthena free cash flow

Eikon Therapeutics, Inc. Common Stock & Prothena appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.